Opportunity timeline
In plain English
Los Alamos National Laboratory is offering TIDAL, a protein-only technology that uses nanobodies to form target-triggered droplets. Potential applications include resin-free protein purification, slow-release drug delivery, intracellular protein trapping, and more sensitive diagnostics. The technology is at TRL 3, has a U.S. patent pending, and is available to companies through exclusive or non-exclusive licensing agreements; this is not a request for outside development services.
About this opportunity
Developed by Los Alamos National Laboratory, TIDAL (Target-Induced Droplet Assembly of Ligands) transforms the small antibody fragments known as nanobodies into a programmable, protein-only material that organizes itself on demand. By harnessing a natural process called liquid-liquid phase separation, TIDAL lets these binders gather into dense, dynamic droplets precisely when they encounter their intended target, giving developers a single platform that can purify proteins without costly resins, deliver drugs as a self-forming slow-release depot and even trap harmful proteins inside living cells. The outcome is a versatile toolkit that lowers production costs, simplifies manufacturing and…
Time remaining
Closes Dec 9, 2026
Related Opportunities

DARPA Surgical Competition (DSC) Industry Day

Cryo-Electron Microscopy (Cryo-EM) Services

Human Hindbrain Organoid Functional Assay Services.

Chemical, Biological, Radiological and Nuclear Advance Defense Enabling Network and Clinical Capability (CADENCC)

Study entitled “Malaria and vector borne disease surveillance in the Colombia/Venezuela border”
Bid details are gathered and summarized automatically. Please verify details at the original source.
Ref No.
BS-CD5E58

